Email This Article

Headlines & Perspectives
ImClone's Erbitux Prolongs Survival: Study
By TSC Staff
09/11/08 - 01:22 AM EDT
Results of a study show that adding Erbitux to a platinum-based chemotherapy in the first-line treatment of the cancer resulted in statistically significant improvement in the primary endpoint of overall survival.
Recipient's Email Address(es)
(Separate multiple addresses with a comma)
Your Email Address
Send a copy to myself
Your Message (optional)

Privacy Policy

The information entered on this page will not be used to send unsolicited email and will not be sold to a 3rd party.

Dow Jones S&P 500 NASDAQ 10-Year Note
10,441.12 1,109.18 2,206.91 35.96
Oil *
73.55
DOWN
10.88
UP
1.25
UP
5.86
DOWN
0.07
10 Yr
3.60%
SPDR Gold
111.59
-0.10%
+0.11%
+0.27%
-0.19%
Data delayed 20 minutes

More From TheStreet

Latest Headlines

Brokerage Partners